Merck has been granted a patent for GPR35 modulators, compounds used in the treatment of diseases, disorders, or conditions. The patent also covers pharmaceutical compositions containing these compounds. One specific claim of the patent is a method of treating inflammatory bowel disease by administering a compound with a specific chemical structure. GlobalData’s report on Merck gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Merck, Human telomerase RT biomarker was a key innovation area identified from patents. Merck's grant share as of September 2023 was 54%. Grant share is based on the ratio of number of grants to total number of patents.
A recently granted patent (Publication Number: US11773101B2) discloses a method for treating inflammatory bowel disease (IBD) in patients. The method involves administering a therapeutically effective amount of a compound or a pharmaceutically acceptable salt or solvate thereof. The compound has a specific chemical structure defined by Formula (I?).
The patent claims provide further details about the compound and its variations. For instance, claim 2 specifies that R1, a component of the compound, can have different configurations. Claim 3 states that p, another component of the compound, can have values of 0, 1, or 2. Claim 4 describes the various possibilities for R5, which can be independently selected from a range of options including halogen, hydroxyl, alkyl groups, and heterocyclic structures.
The subsequent claims (5-14) further refine the possible configurations of R5 and R1, specifying additional options and combinations. Claim 15 focuses on R2, another component of the compound, which can be hydrogen, hydroxyl, alkyl groups, or an alkyl group attached to an oxygen atom. Claim 17 indicates that the compound can have a specific value of n, which is 0.
The patent also covers the treatment of specific types of IBD. Claim 19 specifies that the method can be used for treating Crohn's disease, ulcerative colitis, and perianal Crohn's disease.
In summary, the granted patent discloses a method for treating inflammatory bowel disease using a specific compound or its pharmaceutically acceptable forms. The compound has a defined chemical structure, and the patent claims provide further details about the variations and configurations of its components. The method can be used for treating different types of IBD, including Crohn's disease, ulcerative colitis, and perianal Crohn's disease.
To know more about GlobalData’s detailed insights on Merck, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
